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Introduction
Transcatheter aortic valve implantation (TAVI) has become an al-
ternative therapeutic approach leading to favorable outcomes in 
patients with symptomatic severe aortic valvular stenosis who are 
at high surgical risk or are unsuitable candidates for surgical aortic 
valve replacement.1)2) In general, re-operations after a previous car-
diac surgery are associated with increased mortality and high risk 
for adverse events. Therefore, a history of previous cardiac surgery in 
patients with symptomatic severe aortic stenosis is generally con-
sidered an indication for TAVI. However, concerns still exist over 
treating patients who have previously undergone mitral valve sur-
gery due to the proximity and the potential mechanical interference 
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between the TAVI device and the previously implanted mitral pros-
thesis. There have only been a limited number of reports on the fea-
sibility of TAVI using a CoreValve (Medtronic, Minneapolis, MI, USA) 
in patients with a prosthetic mitral valve. To our knowledge, this is 
the first case regarding this problem in Korea.
In this case report, we present a patient with symptomatic severe 
aortic stenosis and previous mechanical mitral valve replacement 
who was successfully treated with TAVI using a CoreValve. 
Case
A 75-year-old female was referred to our institution due to heart 
failure {New York Heart Association (NYHA) class III} as a consequ-
ence of severe aortic valve stenosis, which was diagnosed at a local 
hospital. The patient had a medical history of mitral valve replace-
ment with a mechanical prosthetic valve (St. Jude #29) in 1988. 
Other comorbidities included hypertension, bronchial asthma, and 
chronic otitis media. The electrocardiogram (ECG) on admission 
showed sinus rhythm and findings suggestive of left ventricular hy-
pertrophy. Transthoracic and transesophageal echocardiography sh-
owed a heavily calcified aortic valve with an aortic valve area of 0.41 
cm2 and peak and mean pressure gradients of 54 and 30 mm Hg, 
respectively (Figs. 1 and 4A). The bileaflet mechanical mitral valve 
was intact without any morphological abnormalities. The left ventri-
cle showed normal systolic function and dimensions with mild con-
centric hypertrophy. There was mild pulmonary hypertension with a 
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right ventricular systolic pressure of 47 mm Hg and mild tricuspidal 
regurgitation. Computed tomography (CT) images demonstrated a 
heavily calcified aortic valve with an annulus diameter ranging from 
18.6 to 23.3 mm, an annulus perimeter of 68.6 mm, and an annulus 
area of 350 mm2. The distance between the prosthetic mitral valve 
and the aortic valve annulus was 4.5 mm. CT angiography demon-
strated moderately tortuous iliac arteries with a diameter greater 
than 5.6 mm and common femoral arteries with a diameter greater 
than 6.4 mm on both sides. There was no significant stenosis or cal-
cification in the iliac or common femoral artery. Coronary angiogra-
phy revealed no significant stenosis. The logistic Euroscore II was 
calculated to be 13.2%. A multidisciplinary heart team consisting of 
interventional cardiologists, cardiac surgeons, anesthesiologists, and 
imaging specialists evaluated the case and approved TAVI for this 
patient.
The procedure was carried out in a hybrid operating room under 
general anesthesia. The vascular access for the CoreValve delivery 
catheter was obtained in the left common femoral artery with stan-
dard percutaneous access techniques. The “Preclose” technique us-
ing two suture-based closure devices (Abbott Vascular, Redwood 
City, CA, USA) was applied before insertion of the sheath in order to 
prepare pre-tied knots for closure of the puncture site after the pro-
cedure. A temporary pacemaker was placed in the right ventricle 
via the right femoral vein. A 5 Fr pigtail catheter was inserted into the 
ascending aorta via the right common femoral artery for angio-
graphic guidance. A 0.032 inch wire was passed through the aortic 
valve using a 5 Fr AL1 catheter and exchanged with a pre-shaped 
0.035 inch superstiff wire. A delivery sheath loaded with a 26 mm 
CoreValve was inserted through the aortic valve without predilation. 
The position of the CoreValve was adjusted within the aortic valve, 
avoiding contact with the prosthetic mitral valve, and was slowly 
deployed under angiographic and transesophageal echocardiogra-
phy probe (TEE) guidance (Fig. 2). TEE after the valve deployment re-
vealed a moderate degree of paravalvular leak. Therefore, postdilation 
A  B  
Fig. 1. Pre-procedural transthoracic echocardiogram with a parasternal long axis view of the heavily calcified aortic valve with valve area of 0.41 cm2. 
A: without color Doppler. B: with color Doppler. AV: aortic valve, LA: left atrium, LV: left ventricle, RV: right ventricle, pMV: prosthetic mitral valve.
A  B  
Fig. 2. Fluoroscopic images of transcatheter aortic valve implantation using a CoreValve. A: partially deployed CoreValve. B: completely deployed CoreValve. 
TEE: transesophageal echocardiography probe, pMV: bileaflet mechanical prosthetic mitral valve (dotted circle), W: superstiff wire inserted into the left 
ventricle, TP: temporary pacemaker inserted into the right ventricle.
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using a 22 mm balloon (Maxi LDTM, Cordis Corporation, Johnson & 
Johnson Ltd., Bridgewater, NJ, USA) was performed under rapid pac-
ing. Subsequent TEE showed a decreased paravalvular leak (mild AR) 
and an adequate position of the implanted CoreValve (Fig. 3). The 
prosthetic mitral valve showed intact valve function. The peak and 
mean pressure gradients over the aortic valve as measured by echo-
cardiography were decreased from 54 to 18 mm Hg and from 30 
to 8 mm Hg, respectively (Fig. 4). The puncture sites were closed 
without vascular complications. The patient was monitored in an 
intensive care unit for two days. No conduction abnormalities were 
observed on ECG. The patient’s symptoms subsequently improved 
from NYHA class III to class I. On day 8 post-procedure, the patient 
was discharged without any significant complications. 
Discussion
Patients with an estimated mortality risk >20% by logistic EuroS-
CORE or >10% by the Society of Thoracic Surgeons score system are 
generally considered candidates for the TAVI procedure. In addition, 
combined respiratory failure; pulmonary hypertension; previous car-
diac surgery; right ventricular failure; hostile thorax caused by oc-
currences such as radiation, burns, previous thoracic pleurodesis, or 
multiple thoracotomies; severe connective tissue disease; liver cir-
rhosis; cachexia; or porcelain aorta are further indications for TAVI.3) 
Also, a history of cardiac surgery is generally associated with in-
creased mortality (5-26%) due to postoperative adhesion and the 
patient’s impaired general condition.4)5)
A  B  
Fig. 3. Post-procedural images of transesophageal echocardiography (135 degree long axis view). A: without color Doppler. B: with color Doppler. The im-
planted CoreValve (arrowheads) did not interfere with the mechanical mitral valve (white arrow). The black arrows indicate a mild degree of paravalvular leak. 
Ao: aorta, LA: left atrium, LV: left ventricle, pMV: prosthetic mitral valve.
A  B  
Fig. 4. Pressure gradient over the aortic valve as measured by transthoracic echocardiography. A: before TAVI. B: after TAVI. Peak/mean pressure gradient was 
reduced from 54/30 mm Hg to 18/8 mm Hg. TAVI: transcatheter aortic valve implantation.
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The technical concerns regarding TAVI in patients with prosthetic 
mitral valves are due to the potential interactions between the aortic 
and mitral prostheses at the anatomic aorto-mitral continuity. The 
significant reduction or even absence of themitroaortic space to ac-
commodate the balloon-expanded valve and the presence of a me-
chanical structure instead of fibrous tissue can limit the expansion 
of the percutaneous valve.6) Therefore, a pre-existing prosthetic 
valve or ring had been considered an exclusion criterion in clinical 
trials such as the PARTNER II trial (Edwards Sapien valve) and the 
Medtronic CoreValve U.S Pivotal Trial.7)8) Several reports have since 
demonstrated that TAVI can be successfully performed in patients 
with mechanical or biological mitral valves or annuloplasty mitral 
rings.6)9-11) However, there have been a limited number of reports on 
TAVI using CoreValve, a self-expandable stent with a longer stent 
frame compared to balloon-expandable valves, in patients with a 
mechanical mitral valve. This is the first Korean case report on this 
issue.
In the present case, we avoided any displacement or deformation 
of the CoreValve and distortion of the preexisting mitral prosthesis 
by meticulous positioning of the TAVI device under TEE guidance. 
Also, post-procedural echocardiography revealed intact mitral valve 
function. Pre-procedural assessment using echocardiography and 
CT images are important to avoid potential interference between the 
aortic annulus and the mitral prosthesis. The intraprocedural imag-
ing guidance by TEE is critical to adjust the extent of the prosthetic 
valve strut protrusion into the LVOT. 
Our case demonstrates that TAVI using a CoreValve can be per-
formed safely in patients with previously implanted prosthetic mitral 
valves. 
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